Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Engage Grants Program

University of Western Ontario

$25,000.00

Calcification abatement in pericardial tissue for bioprosthetic heart valve

EF 2010-11

Résumé
Heart valve disease is prevalent among the Canadian population and worldwide. Worldwide, it is estimated that 290,000 heart valve replacement procedures were performed in 2003. This number is projected to triple to over 850,000 in 2050. Improvement in replacement heart valve technology especially that would improve the limited durability of the bioprosthetic heart valves fabricated from either porcine aortic valves or bovine pericardium would bring significant benefits to the patients in terms of both quality of life and durability. Tissue calcification has been identified as a main cause of bioporsthetic heart valve failure. We propose to investigate the use of the dipolar aprotic solvent dimethyl sulfoxide (DMSO) prior to tissue fixation as a means to reduce calcification. Our prior work has demonstrated that DMSO treatment is effective in membrane lipid removal and improvement in tissue shear mechanical properties. We hypothesize that this treatment would also lead to a reduction in calcification and therefore an increase in heart valve durability. Patients would directly benefit from an extended lifetime for the improved bioprosthetic heart valve. In addition, Canada will also benefit from the technology developed in terms of increased business opportunities.
Programme
Engage Grants Program
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
412001-2010
Name nom
Wan, WanKei
Department département
Chemical and Biochemical Engineering
Organization id
36
Institution établissement
University of Western Ontario
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1553
Committee name en
Ontario Internal Decision Committee
Committee name fr
Comité de décision interne pour l'Ontario
Area of application code
1211
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Medical and health sciences
Area of application fr
Sciences médicales et de la santé
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Partie
1
Nb partie
1
Application title
Calcification abatement in pericardial tissue for bioprosthetic heart valve
Keyword
NSERC
Application summary
Heart valve disease is prevalent among the Canadian population and worldwide. Worldwide, it is estimated that 290,000 heart valve replacement procedures were performed in 2003. This number is projected to triple to over 850,000 in 2050. Improvement in replacement heart valve technology especially that would improve the limited durability of the bioprosthetic heart valves fabricated from either porcine aortic valves or bovine pericardium would bring significant benefits to the patients in terms of both quality of life and durability. Tissue calcification has been identified as a main cause of bioporsthetic heart valve failure. We propose to investigate the use of the dipolar aprotic solvent dimethyl sulfoxide (DMSO) prior to tissue fixation as a means to reduce calcification. Our prior work has demonstrated that DMSO treatment is effective in membrane lipid removal and improvement in tissue shear mechanical properties. We hypothesize that this treatment would also lead to a reduction in calcification and therefore an increase in heart valve durability. Patients would directly benefit from an extended lifetime for the improved bioprosthetic heart valve. In addition, Canada will also benefit from the technology developed in terms of increased business opportunities.